Ani Pharma Private Limited - Due diligence report

A 360° intelligence report on Ani Pharma: trust score, financial health, credit view, compliance, directors, growth and distress signals - g…

2015-01-20 Jalgaon, Maharashtra Strike Off Unlisted Active Compliant
Share
View plans
AP Ani Pharma Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹349 50% off New user
Or enjoy up to 50% off with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Ani Pharma — 360° Intelligence Report

Generated from MCA filings & public records
58/100
Trust Score
Moderate

Ani Pharma is assessed as Moderate with a Trust Score of 58/100. Ani Pharma is a private limited indian non-government company incorporated in 2015, operating in the Healthcare sector. Processed financial statements are not yet available for trend analysis. Based on MCA filings and public records, it currently shows a high compliance risk and moderate financial risk profile.

Report generated on 29 Jun 2026 from the latest processed filings. Ani Pharma Private Limited snapshot & full profile →

Financial Health › Neutral
Overall Assessment CautionWeakNeutralGoodStrong Good
Compliance › Weak

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
58/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreCaution Indicated
30/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
50/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
80/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreNo Data
N/A
Needs at least two filed years to measure growth.
Distress ScoreModerate
55/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 1 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 80/100 Low Risk
  • Liabilities ≈ 38% EBITDA - serviceable.
  • No open charges - unencumbered balance sheet.
  • Working-capital cover adequate.

Charges position: 0 open (-) · 0 satisfied (-).

Compliance Score: 30/100 Caution Indicated
  • Company status is "Strike Off" - not Active.
  • Last balance sheet is for Mar 2021 - filings overdue.
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
ANIKET ANANT KULKARNI 01234567 Director 01/04/2018 6 yrs Approved
ANANT KALIDAS KULKARNI 01234567 Director 01/04/2018 6 yrs Approved
  • 2 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
06

Ownership & Group Intelligence

As per FY 2017 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
1 allotment(s) · 0 transfer(s)

Promoters hold the largest single block of equity - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth N/A · Distress 55
Growth signals & trust indicators
Operating for 11+ years.
Distress signals & risk flags
Statutory filings appear overdue.
Adverse company status: Strike Off.
Compliance score is weak (30/100).
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence46/100
Review suggested
Suitability as a supplier / customer counterparty.
  • Check the compliance flags before onboarding.
  • 2 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment58/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance gaps should be priced into terms.
Investor view32/100
Limited indicators at present
Growth quality and scalability through an investor lens.
  • No clear growth signals in the filed years.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 6 events
30 Nov 2021
Last AGM held
Annual general meeting
31 Mar 2021
Latest balance sheet
Filed with ROC
06 May 2016
Securities allotted
29600 Equity Shares Without Differential Rights - 2.96 Lakh raised
20 Jan 2015
Incorporated
Registered with Roc Mumbai
Director appointed
ANIKET ANANT KULKARNI (Director)
Director appointed
ANANT KALIDAS KULKARNI (Director)
10

Key Observations

Auto-generated from the data above
2 active director(s) / partner(s); board looks stable and experienced.
Promoters hold the largest single block of equity as per the FY 2017 annual return.
Capital has been raised through 1 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Ue Marketing Private Limited U51909MH2003PTC139440 Mumbai, Maharashtra, India
Akshar Pharma Private Limited U51397MH2002PTC135935 Mumbai, Maharashtra, India
Matrix Global Private Limited U51103DL2007PTC169997 New Delhi, Delhi, India
Alpha Meditech Private Limited U24232DL2008PTC186163 New Delhi, Delhi, India
Swarn Artificial Aids Private Limited U93000DL2007PTC164055 New Delhi, Delhi, India
Orthodontic Supplies U74140DL2015PTC286699 Delhi, Delhi, India
Preetikaya Lifestyle Solutions Private Limited U18101MH2014PTC260089 Mumbai, Maharashtra, India
Ksd Distributors & Services Private Limited U51909WB2015PTC206873 Kolkata, West Bengal, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Ani Pharma before audits and certifications: compliance score 30/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Ani Pharma: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 80/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Limited indicators at present. Growth score n/a, margin trends, ownership structure and peer set for Ani Pharma - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Review suggested. Trust score 58/100, distress signals and MSME payment-delay disclosures - know whether Ani Pharma pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Ani Pharma - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Ani Pharma an active company?

Ani Pharma has MCA status “Strike Off” with a compliance score of 30/100 (Caution Indicated).

Is Ani Pharma financially healthy?

Ani Pharma has a Financial Health Score of 50/100 (Moderate) based on its filed financial statements.

Should I do business with Ani Pharma?

Its overall Trust Score is 58/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Ani Pharma?

Promoters hold the largest single block of equity - exact percentages are in the full report. 2 active director(s) are on record.

Does Ani Pharma have loans or charges against its assets?

No charges are registered against this company - an unencumbered balance sheet.

Is Ani Pharma up to date with its ROC filings?

Last balance sheet is for Mar 2021 - filings overdue. Overall compliance score: 30/100 (Caution Indicated).

Is it risky to lend to Ani Pharma?

Its Credit Risk Score is 80/100 (Low Risk). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.